PFE vs. TECH: Pfizer vs. Bio-Techne Stock Comparison

November 11, 2026

How do Pfizer (PFE) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Pfizer (PFE) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PFE is classified in Pharmaceuticals while TECH is classified in Life Sciences Tools & Services.

Company profile comparison for Pfizer (PFE) and Bio-Techne (TECH)
Profile Item	PFE	TECH
Name	Pfizer Inc.	Bio-Techne Corp.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Life Sciences Tools & Services
GICS Sub-Industry	Pharmaceuticals	Life Sciences Tools & Services
Market Capitalization	167.52 billion USD	11.43 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	June 1, 1972	February 9, 1989
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

PFE

TECH

GSPC

Pfizer (PFE) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Pfizer (PFE) and Bio-Techne (TECH). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Pfizer (PFE) and Bio-Techne (TECH). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Pfizer (PFE) and Bio-Techne (TECH)
Metric	PFE	TECH
Total Return (1Y)	28.65%	27.56%
Total Return (3Y, Annualized)	6.41%	9.11%
Total Return (5Y, Annualized)	-3.98%	-9.91%

Risk Profile

Drawdown History

PFE

TECH

GSPC

Pfizer (PFE) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Pfizer (PFE) and Bio-Techne (TECH). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Pfizer (PFE) and Bio-Techne (TECH)
Metric	PFE	TECH
Volatility (1Y, Annualized)	21.72%	43.08%
Beta (5Y)	0.35	1.26
Max Drawdown (5Y)	-58.96%	-65.87%
Avg. Volume (3M)	33.67M	2.81M

Risk-Adjusted Performance

Risk-Return Positioning

PFE and TECH are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Pfizer (PFE) and Bio-Techne (TECH)
Metric	PFE	TECH
Sharpe Ratio (1Y)	1.12	0.54
Sortino Ratio (1Y)	1.73	0.82

Profitability

ROE (TTM)

Bio-Techne (TECH) at 8.33% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for TECH.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.47%

Max: 109.18%
Q3: 6.23%
PFE: 4.47%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.33%

Max: 109.18%
TECH: 8.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both Pfizer (PFE) at 6.34% and Bio-Techne (TECH) at 14.00% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.34%

Max: 18.05%
PFE: 6.34%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.00%

Max: 18.05%
TECH: 14.00%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Pfizer (PFE) at 33.38% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.38%

Max: 83.12%
PFE: 33.38%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.21%

Max: 83.12%
Q3: 14.77%
TECH: 12.21%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Pfizer (PFE) and Bio-Techne (TECH)
Metric	PFE	TECH
ROE (TTM)	4.47%	8.33%
ROA (TTM)	5.59%	6.38%
Net Margin (TTM)	6.34%	14.00%
Operating Margin (TTM)	33.38%	12.21%
Gross Margin (TTM)	74.90%	66.23%

Growth

Revenue Growth

Bio-Techne (TECH) at -0.38% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their Revenue Growth across different time periods.

EPS Growth

Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while Pfizer (PFE) at -3.55% is closer to the peer norm — faster per-share earnings growth for TECH.

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Pfizer (PFE) and Bio-Techne (TECH)
Metric	PFE	TECH
Revenue Growth (YoY)	-1.65%	-0.38%
Revenue Growth (3Y CAGR)	-14.80%	2.25%
EPS Growth (YoY)	-3.55%	152.17%
EPS Growth (3Y CAGR)	-37.12%	-12.97%

Financial Strength

Current Ratio (MRQ)

Both Pfizer (PFE) at 1.42 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.42

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
PFE: 1.42
Min: 0.10

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.28

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TECH: 2.28
Min: 0.10

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Techne (TECH) at 0.13 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71

Max: 1.42
PFE: 0.71
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.13

Max: 1.42
Q3: 0.65
Median: 0.15
TECH: 0.13
Q1: 0.02
Min: 0.00

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Pfizer (PFE) and Bio-Techne (TECH)
Metric	PFE	TECH
Current Ratio (MRQ)	1.42	2.28
Debt / Equity (MRQ)	0.71	0.13
Net Debt / EBITDA	1.97	-0.20

Dividends

Dividend Yield (TTM)

Both Pfizer (PFE) at 7.30% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.30%

PFE: 7.30%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.44%

TECH: 0.44%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Bio-Techne (TECH) reports 27.59%, ranking against industry peers normally.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

245.71%

PFE: 245.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.59%

TECH: 27.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Pfizer (PFE) and Bio-Techne (TECH)
Metric	PFE	TECH
Dividend Yield (TTM)	7.30%	0.44%
Dividend Payout Ratio (TTM)	245.71%	27.59%

Valuation

P/E Ratio (TTM)

Pfizer (PFE) at 41.99 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.99

Max: 85.34
Q3: 43.46
PFE: 41.99
Median: 26.69
Q1: 13.30
Min: 0.07

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

62.74

Max: 85.34
TECH: 62.74
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Bio-Techne (TECH) at 9.31 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
PFE: 2.63
Min: 0.01

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.31

Max: 58.18
Q3: 25.77
TECH: 9.31
Median: 7.30
Q1: 3.01
Min: 0.01

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Pfizer (PFE) at 1.88 and Bio-Techne (TECH) at 5.28 are valued close to their industries’ norm against book — neither stands out from peers.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.88

Max: 13.53
Q3: 6.54
Median: 3.25
PFE: 1.88
Q1: 1.69
Min: -5.59

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max: 13.53
Q3: 6.54
TECH: 5.28
Median: 3.25
Q1: 1.69
Min: -5.59

Pfizer (PFE) vs. Bio-Techne (TECH): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Pfizer (PFE) and Bio-Techne (TECH)
Metric	PFE	TECH
P/E Ratio (TTM)	41.99	62.74
P/S Ratio (TTM)	2.63	9.31
P/B Ratio (MRQ)	1.88	5.28
Free Cash Flow Yield (TTM)	7.76%	2.39%